EP1003500A1 - Intramurale verabreichung von stickstoff monoxid zur hemmung der läsionsbildung nach einer gefässverletzung - Google Patents

Intramurale verabreichung von stickstoff monoxid zur hemmung der läsionsbildung nach einer gefässverletzung

Info

Publication number
EP1003500A1
EP1003500A1 EP97938163A EP97938163A EP1003500A1 EP 1003500 A1 EP1003500 A1 EP 1003500A1 EP 97938163 A EP97938163 A EP 97938163A EP 97938163 A EP97938163 A EP 97938163A EP 1003500 A1 EP1003500 A1 EP 1003500A1
Authority
EP
European Patent Office
Prior art keywords
injury
catheter
balloon
arginine
precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97938163A
Other languages
English (en)
French (fr)
Other versions
EP1003500A4 (de
Inventor
John P. Cooke
Sverin Schwarzacher
Tai T. Lim
Alan C. Yeung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/695,792 external-priority patent/US5852058A/en
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of EP1003500A1 publication Critical patent/EP1003500A1/de
Publication of EP1003500A4 publication Critical patent/EP1003500A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • Intravenous oral administration of L-arginine can enhance the release of endothelium-derived nitric oxide from vessels of animals or humans with hypercholesterolemia and/or atherosclerosis ( 1 -8)
  • Chronic oral administration of L-arginine also inhibits the development of atherosclerosis in hypercholesterolemic animals (9-10)
  • Oral administration of L-arginine also inhibits restenosis following balloon injury (1 1- 13) as does oral L-arginine combined with application of L-arginine to the external surface of the vessel using a pluro ⁇ ic gel ( 14)
  • oral or intravenous administration of L-arginine has systemic side-effects
  • Oral or intravenous L-arginine is known to induce the release of growth hormone and insulin, this could potentially exacerbate hyperglycemia in patients with diabetes
  • high doses of oral arginine can increase the proliferation of tumor cells in human breast cancer
  • SUMMARY OF fHE I NVENTION Methods and devices are provided for inhibiting the pathology associated with vascular injury, particularly during angioplasty and atherectomy
  • An NO precursor particularly L-arginine
  • Various conventional delivery devices may be used for intramui al delivery of the NO precui sor which are loaded with the NO precursor
  • FIGS 1 A and I B are schematic diagrams explaining the treatment and experimental protocol of the acute study (FIG 1 A) and the chronic study (FIG IB)
  • FIG 2A shows the endothelium-dependent vasomotion before and following the local delivery of L-arginine
  • the Y axis shows % constriction and dilatation
  • the X axis the course of the expenment Befoi e the L-arginme thei e w as only a minor change in diameter in both iliac arteries
  • FIG 2B is a graph showing that the vessel segments distal to the delivery site did show only minor changes in vessel diameter to acetylcholine and were not affected by the L-arginine delivery
  • FIG 3 is a representative aortogram in the hypercholesterolemic rabbit Before Ach infusion (left panel, 10 S M
  • FIG 6 depicts low power microphotographs of iliac arteries of hypercholesterolemic rabbits 4 weeks after balloon catheter injury and local drug delivery Intimal thickening is markedly reduced in the vessel segment treated with L- argmine (right) in a comparison to that treated with vehicle (left)
  • FIG 7 are histograms illustrating the percentage of intimal lesion occupied by macrophages In vessel segments H eated w ith L-arginine ( stuped bai s) macrophage accumulation did not exceed 20% of the intimal ai ea By contrast in vehicle treated segments macrophages occupied up to 70% of the intimal area in some cases
  • FIG 8 is a fragmentary view, partially in section of a drug delivery apparatus for use in the subject invention positioned in a blood vessel with the dilatation balloon in its inflated state and containing a solution of an NO precursor
  • FIG 9 is a fragmentary iew, partially in section, of the NO precursor drug delivery apparatus positioned in a blood vessel and embodying iontophoresis means to transport the drug across the balloon surface
  • the method provides introducing into the vessel walls at the site of injury an NO precursor, which results in the enhancement of NO production in the cells at the site of injury
  • NO precursor which results in the enhancement of NO production in the cells at the site of injury
  • Various delivery systems may be employed which result in the NO forming agent infusing into the vessel wall, and being available to the cells for NO production
  • Devices which may be employed include drug delivery balloons, e g porous, sonophoretic, and lontophoretic balloons, as exemplified by the devices depicted in W092/1 1895 WO95/05866 and WO96/08286, as well as such commercial devices as Dispatch® ( Scimed) See also Santoian et al , Cath Caidiov Diag ( 1993) 30 34S-354, Mullet et al I lin ( oil ( itiiliol ( !
  • the NO precui sor agent is introduced in a delivers' balloon for transport bv a catheter to the sue of iury
  • the balloon may then be expanded under pressure driving the agent from the balloon into the surrounding vessel wall
  • the amount of agent which is employed may vary depending upon the nature of the agent, the region to be treated, and the loss of the agent from the region
  • the infusion of the agent is maintained for sufficient time to ensure that the cells and extracellular matrix in the iniury region are exposed to the agent, so as to enhance the production of NO by these cells
  • the agent may have a single active ingredient or be a combination of active ingredients Of particular interest aie the ammo acids, L-arginine and L-lysine, individually or in combination, as a mixture or as a oligopeptide, or a biologically equivalent compound, such as low molecular weight oligopeptides having from about 2-10 usually 2-6
  • ⁇ physiologically acceptable medium will be employed, normally an aqueous medium which may be deionized water, saline, phosphate buffered saline, etc
  • the amount of the active NO precursor agent will vary depending upon the particular agent employed the other additives present, etc Generally, as exemplified by L-arginine, at least about 50 mg will be present and not more than about 5 g, usually at least about 100 mg and not more than about 2 ⁇ j li equentlv at least about 500 mg
  • the concentration mav be va ⁇ ed widely, generally ranging from about 20-500 more usually from about 50-250 g/l
  • the time for the treatment will usually be at least about 2 minutes, and not more than about 0 5 hour, generally ranging from about 5- 1 5 minutes
  • the rate of introduction will generally range from about 0 05-5 ml/min, depending upon all of the other factors
  • the subject methodology is employed with hosts who have suffered vascular iniurv, as caused by ang ⁇ oplast ⁇ and atherectomies
  • the time for the administration of the NO precursor agent mav be va ⁇ ed widely, pi ovidmg a single administration oi multiple administrations over a relatively short time period in relation to the ime oi injury
  • treatment may be befoi e, concurrently or after the injury, usually within 2 weeks of the in-ury, if before, and not more than about 8 weeks, usually not more than about 6 weeks, preferably in the range of 0-6 weeks (where 0 intends concurrrently or shortly after the prior procedure within 6 hours)
  • the patients will be suffering from various conditions associated with narrowed vessels, particularly hypercholesterolemia, diabetes, tobacco use and hypertension
  • various conditions associated with narrowed vessels particularly hypercholesterolemia, diabetes, tobacco use and hypertension
  • one will normally be dealing with vessels which are narrowed to v ⁇ rying degrees as a lesult of the accumulation of plaque at the vessel wall
  • FIG. 8 illustrates the drug delivery apparatus with the balloon 12 in its inflated state and within an arterial vessel in which the vessel walls are indicated by the reference numeral 15
  • PCTA percutaneous transluminal coronary angioplasty
  • the guide wire 10 is first inserted into the selected artery to a point past the stenotic lesion
  • the dilatation catheter including the catheter body 1 1 and the balloon 12 is then advanced along the guide wire 10 to the desired position in the artei lal system in which the balloon portion 12 traverses or crosses the stenotic lesion
  • the balloon 1 2 is then inflated bv inti oducing the NO pi ecursor solution through the balloon lumen 14 into the interior chamber 1 of the balloon 12
  • the outer surfaces of the balloon 12 press outwardly against the inner surfaces of the vessel wall 15 to expand or dilate the vessel in the area of the stenotic lesion, thus performing the angioplasty portion of the method as well as the intramural introduction of the NO precursor into the vessel
  • the porous balloon may be made from any of the conventional materials used for this purpose These include cellulose acetate, polyvmyl chloride, polysulfone, polvacrvlonit ⁇ le, polvui ethanes natui al and synthetic elastomei s polvolefins, polvestes, fluoropolymci s, etc Usually the film thickness willbe in the range of about 10A to l ⁇ , with a nominal poie size oi about 0 05 to I ⁇ Alternatively, a local drug delivery system mav be employed where the agent is delivered to the vessel wall by channels that are on the exterior surface of the balloon The balloon is placed into the diseased vessel segment as described above The balloon is then inflated in the usual manner (using saline, usually containing a contrast agent), placing the channels (on the sui tace of the balloon) in contact with the vessel wall The NO precursor solution is then infused under pressure into the channels Perforations in the channels allow the solution to exit and
  • Figure 9 illustrates a structure utilizing iontophoresis to assist in driving the active NO precursor across the balloon wall 26 and into contact with the vessel walls 1 5
  • One electrode 28 the catheter electrode, is located on or within the catheter body 1 1
  • the other electi ode 1 the body surface electrode is located on the body surface or within the body ot the patient ⁇ n elenncal cun ent loi the lontophoi etio pi ocess is pioduced between the electrodes 28 and 3 I by an external power soui ce 30 through the electrical leads 29 and 33, respectively
  • Direct cui i enl mav be used although other wave lorms are also utilized (e g , a series of rectangular waves producing a frequency of 100 Hz or greater)
  • the balloon 26 is first positioned across the stenotic lesion
  • the balloon interior 27 is then inflated with the drug in the lumen 23 As the balloon expands, it causes the artery to dilate This is followed by activating the power supply 30 thereby creating a current between the electrode 28 and the electrode 3 1 which passes through the balloon w all 26 1 his cu ⁇ ent drives or drags the NO precursor within the chamber 27 aci oss the wall and into contact with the surrounding vessel wall 1 5 and vascular tissue
  • a local drug delivery balloon (3 mm, Dispatch®, Scimed) was advanced to the left or right iliac artery and placed at the same position as the previous balloon injury
  • the proximal end of the delivery catheter was placed at the internal iliac branch under fluoroscopic conti ol foi landmai i eference
  • the balloon was inflated to six atmospheres and L-aiginme (800 mg/5 ml), or saline w as infused for 1 minutes at a rate of 0 2 ml/minute Subsequently, this procedure was repeated in the contralateral iliac artery
  • the iliac artery to receive arginine treatment was randomly determined
  • An intravenous bolus injection of Kefzol® was given for prevention of infections
  • a control angiogram was obtained Subsequently two infusions containing acetylcholine ( 10 s 10 6 M) were administered at a rate of 0 8 ml/minute for 3 minutes through a Swan Ganz catheter (4 French in diameter), placed above the iliac bifurcation Immediately following each infusion an angiogram of the iliac arteries was performed All angiograms were measured blindly by two investigators with an electronic cahper system The diameter was measured at three predetermined sites along the area of drug delivery at baseline and after each dose of acetylcholine before and after the local drug delivery The vessel diameter was also measured at a reference site distal to the infusion segment to verify downstream effects of localK deln ei ed L-ai gini ⁇ e The percent vanation in diameter compared to baseline was calculated for each dose and expressed in mean ⁇ SEM
  • Hai vesting of 7 issue 30 to 60 minutes following the local delivery of L-argmme animals were sacrificed and the iliac arteries carefully freed from adjacent tissue Care was taken to harvest the exact portion of the artery where the local delivery was carried out by matching the anatomy with the respective fluoroscopic picture
  • balloon electron microscopv of the delivered segment was pei toi med in t i ee rabbits
  • the harvested iliac artery rings were placed in cold physiological solution
  • the vessel was opened longitudinally and incubated in 2 ml of Hanks buffered saline (HBSS) medium (Irvine Scientific ) containing calcium lonophore ( 1 ⁇ mol/L, A23 1 87
  • samples of the medium were collected for measurements of nitrogen oxide (NOx) and replaced with 2 ml of fresh media After incubation, the segment was weighed and NOx was measured with a commercially available chemiluminescence apparatus (model 2108, Dasibi) 100 ⁇ l of the samples were in-ected into a reduction chamber containing boiling acidic vanadium
  • Figure 2 A shows the response of vessel segments to acetylcholine before and after the local delivery of L-arginine or saline.
  • Baseline vessel diameters were identical before and after local drug delivery in both iliac arteries There was little change in vessel diameter before local drug delivery.
  • NOx measurements were made in vessel segments harvested 30-60 minutes after local drug delivers' Vessel segments treated with arginine exhibited a significant increase in nitrogen oxide levels throughout the incubation periods of 30, 60 and 120 minutes
  • Figure 5 shows the results obtained two and four weeks following local drug delivery Administration of L-arginine significantly inhibited mtimal lesion formation in comparison to vehicle control This phenomenon was even more apparent four seeks following local drug delivery I nuinohistochemisti v
  • Figure 7 shows the percentage of the intimal lesion surface area which stained positively for macrophages Only 0- 10% of the intimal area was infiltrated by positively stained cells in the L-arginine treated segments whereas in vessel segments treated with vehicle the mtimal area involved by macrophages was markedly higher, in some segments exceedinu ⁇ 0 u o ol the mtimal area
  • NO production ex vivo was significantly higher one week following the delivery of L-arginine compared to segments exposed to vehicle These levels were also higher compared to those achieved one hour following the delivery ( Figure 4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97938163A 1996-08-12 1997-08-07 Intramurale verabreichung von stickstoff monoxid zur hemmung der läsionsbildung nach einer gefässverletzung Withdrawn EP1003500A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US695792 1996-08-12
US08/695,792 US5852058A (en) 1993-06-11 1996-08-12 Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
PCT/US1997/013905 WO1998006389A1 (en) 1996-08-12 1997-08-07 Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury

Publications (2)

Publication Number Publication Date
EP1003500A1 true EP1003500A1 (de) 2000-05-31
EP1003500A4 EP1003500A4 (de) 2004-06-23

Family

ID=24794481

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97938163A Withdrawn EP1003500A4 (de) 1996-08-12 1997-08-07 Intramurale verabreichung von stickstoff monoxid zur hemmung der läsionsbildung nach einer gefässverletzung

Country Status (4)

Country Link
EP (1) EP1003500A4 (de)
JP (1) JP2000516612A (de)
DE (1) DE69637676D1 (de)
WO (1) WO1998006389A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6587718B2 (en) 1999-10-08 2003-07-01 Scimed Life Systems, Inc. Iontophoretic delivery to heart tissue
US6706274B2 (en) 2001-01-18 2004-03-16 Scimed Life Systems, Inc. Differential delivery of nitric oxide
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
EP3556401A1 (de) 2005-05-27 2019-10-23 The University of North Carolina at Chapel Hill Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen
ES2958410T3 (es) 2009-08-21 2024-02-08 Novan Inc Geles tópicos
EP2467173B8 (de) 2009-08-21 2019-06-19 Novan, Inc. Wundverbände, verfahren zu ihrer anwendung und verfahren zu ihrer herstellung
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0483614A1 (de) * 1990-10-30 1992-05-06 Clintec Nutrition Company Verwendung von Aminosäuren zum Schutz von ischemischem Herzgewebe und dessen metabolischer Wiederherstellung
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
WO1995005866A1 (en) * 1993-08-27 1995-03-02 Cortrak Medical Inc. Simultaneous angioplasty and drug delivery
WO1995024898A1 (en) * 1994-03-17 1995-09-21 Comedicus, Incorporated Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents
WO1996000112A1 (en) * 1994-06-23 1996-01-04 Cormedics Corp. Vascular treatment method and apparatus
WO1997016983A1 (en) * 1995-11-09 1997-05-15 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236413B1 (en) * 1990-05-07 1996-06-18 Andrew J Feiring Method and apparatus for inducing the permeation of medication into internal tissue
US5499971A (en) * 1990-06-15 1996-03-19 Cortrak Medical, Inc. Method for iontophoretically delivering drug adjacent to a heart
US5428070A (en) * 1993-06-11 1995-06-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0483614A1 (de) * 1990-10-30 1992-05-06 Clintec Nutrition Company Verwendung von Aminosäuren zum Schutz von ischemischem Herzgewebe und dessen metabolischer Wiederherstellung
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
WO1995005866A1 (en) * 1993-08-27 1995-03-02 Cortrak Medical Inc. Simultaneous angioplasty and drug delivery
WO1995024898A1 (en) * 1994-03-17 1995-09-21 Comedicus, Incorporated Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents
WO1996000112A1 (en) * 1994-06-23 1996-01-04 Cormedics Corp. Vascular treatment method and apparatus
WO1997016983A1 (en) * 1995-11-09 1997-05-15 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9806389A1 *

Also Published As

Publication number Publication date
WO1998006389A1 (en) 1998-02-19
EP1003500A4 (de) 2004-06-23
JP2000516612A (ja) 2000-12-12
DE69637676D1 (de) 2008-10-23

Similar Documents

Publication Publication Date Title
US5852058A (en) Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US5861168A (en) Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US6425881B1 (en) Therapeutic mixture useful in inhibiting lesion formation after vascular injury
Moncada et al. Biosynthesis of nitric oxide from L-arginine: a pathway for the regulation of cell function and communication
Barton et al. Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension
Bravenboer et al. Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat
Evangeliou et al. Carnitine metabolism and deficit-when supplementation is necessary?
Vaziri et al. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension
Allen et al. Nitrite and nitric oxide metabolism in peripheral artery disease
Powell et al. Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors
CA2270619A1 (en) Methods for promoting wound healing and treating transplant-associated vasculopathy
Lyons Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease
EP1003500A1 (de) Intramurale verabreichung von stickstoff monoxid zur hemmung der läsionsbildung nach einer gefässverletzung
Peters et al. From rats to man: a perspective on dietary L-arginine supplementation in human renal disease.
Laurent et al. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans
US20030212135A1 (en) Pharmacotherapy for vascular dysfuntion associated with deficient nitric oxide bioactivity
EP0583865B1 (de) Prevention und Behandlung von Atherosclerosis
Erman et al. Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man
CN114980878A (zh) 用于预防和治疗化疗副作用的包含氨基酸的组合物
Nguyen et al. Intravenous administration of piceatannol, an arginase inhibitor, improves endothelial dysfunction in aged mice
Lau et al. Phosphate-binding capacities of calcium and aluminum formulations
US20050176829A1 (en) Methods for treating hypothyroidism
Takagi et al. Aortic arch aneurysm with dissection in Cushing syndrome
Gude Endothelium-derived relaxing factor (nitric oxide) and the placenta
Chetty The do’s and don’ts of arginine supplementation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20040507

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61N 1/30 B

Ipc: 7A 61M 29/02 B

Ipc: 7A 61M 25/10 B

Ipc: 7A 61K 31/195 A

17Q First examination report despatched

Effective date: 20061219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090408